Clinical trials: Residual Disease
Lung Cancer, Non-Small Cell
Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
This trial is a multicenter, open-label, non-interventional controlled study to identify and characterize epigenetic signatures of lung cancer.
- Trial name
- LumenDx (NCT06963307)
- Where
- Israel
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Advanced Lung Non-Small Cell Carcinoma
ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)
- Trial name
- CR1STAL (NCT05198154)
- Testing
- ctDNA detection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fang Wu
Follicular Lymphoma
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
Prospective, multicenter, open label, phase III randomized clinical trial in previously untreated Follicular Lymphoma in early stage. Patients will be randomized to receive Radiotherapy or Radiotherapy plus Obinutuzumab.
- Trial name
- FIL_GAZEBO (NCT05929222)
- Testing
- Radiotherapy, Radiotherapy plus Obinutuzumab
- Where
- 49 sites in Italy
- Volunteers
- 190 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Disease, Hodgkin
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of…
- Trial name
- NCT01100502
- Testing
- brentuximab vedotin
- Where
- 87 sites in United States, Bulgaria and 11 more
- Volunteers
- 329 people
- Sponsor
- Seagen Inc.
Breast Cancer
Intraoperative Detection of Residual Cancer in Breast Cancer
This is a non-randomized, open-label, multi-site study to collect safety and efficacy data on an intraoperative imaging system, the LUM Imaging System (LUM015 imaging agent in conjunction with the LUM imaging device), in…
- Trial name
- NCT03321929
- Testing
- LUM Imaging System
- Where
- 16 sites in United States
- Volunteers
- 234 people
- Sponsor
- Lumicell, Inc.
Multiple Myeloma
VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)
Protocol DSMM VIII is a multi-center, open-label study evaluating the safety and tolerability, as well as the efficacy, of maintenance treatment with VELCADE (bortezomib) in patients with multiple myeloma with detectable disease…
- Trial name
- NCT00311337
- Testing
- bortezomib
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 61 people
- Sponsor
- University of Wuerzburg
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
MCLA-117 in Acute Myelogenous Leukemia
This is a First-in-Human, single arm, open-label, multi-national study designed to determine the safety, tolerability and preliminary efficacy of MCLA 117.
- Trial name
- NCT03038230
- Testing
- MCLA-117 bispecific antibody
- Where
- 9 sites in United States, Belgium and 3 more
- Volunteers
- 80 people
- Sponsor
- Merus B.V.
D010051, Ovarian Cancer
Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery
This study, organized by the European Society of Gynaecological Oncology (ESGO), evaluates the clinical impact of adherence to ten ESGO-established quality indicators (QIs) in advanced ovarian cancer surgery.
- Conditions
- D010051, Ovarian Cancer, Advanced-stage Ovarian Cancer, FIGO Stages III and IV
- Trial name
- retroESGO ov1 (NCT07567573)
- Testing
- Preoperative Evaluations, Cytoreductive Surgery, Perioperative Management
- Where
- Belgium
- Volunteers
- 11,383 people
- Sponsor
- European Society of Gynaecological Oncology
Arthritis, Psoriatic, Ultrasonography
Ultrasound in Psoriatic Arthritis Treatment
BACKGROUND Psoriatic arthritis (PsA) is a systemic inflammatory disease with articular and extra-articular features. Establishing the prognosis of a patient with PsA is hence important to define the treatment strategy.
- Conditions
- Arthritis, Psoriatic, Ultrasonography, Minimal Disease, Residual
- Trial name
- UPSTREAM (NCT03330769)
- Testing
- New course of treatment
- Where
- 4 sites in Italy
- Volunteers
- 250 people
- Sponsor
- University of Cagliari
Chronic Lymphocytic Leukemia (CLL)
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
This is a Phase 2, multicenter, open-label uncontrolled interventional study aimed a determining therapeutic benefits of the addition of ibrutinib to 12 months of venetoclax (single-agent for 6 months then combined with rituximab…
- Trial name
- VALUABLE (NCT04758975)
- Testing
- Venetoclax, Rituximab, Ibrutinib
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- Paolo Ghia
Esophageal Carcinoma, Minimal Residual Disease
Minimally Residual of Esophageal Cancer 001
This trial aims to assess changes in minimal residual disease (MRD) status before and after radical concurrent chemoradiotherapy combined with immunotherapy and adjuvant immunotherapy after neoadjuvant immunochemotherapy in…
- Trial name
- ECMRD-001 (NCT05952661)
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Hebei Medical University Fourth Hospital
Phase 2 Study, Blinatumomab
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
To find out if giving blinatumomab as injections under the skin can help to control MRD and keep the disease from coming back in participants with B-cell ALL.
- Conditions
- Phase 2 Study, Blinatumomab, Acute Lymphoblastic Leukemia
- Trial name
- NCT07192237
- Testing
- Blinatumomab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Age-Related Macular Degeneration
Detection of Topographic Residual Acuity in Patients With Age Related Macular Degeneration
Standard perimetry provides information on topographical retinal sensitivity to light stimuli, however the said locus is not necessarily the preferred locus for fixation.
- Trial name
- NCT00329277
- Testing
- perimetry
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Acute Myeloid Leukemia
Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients
Purpose: The purpose of this trial is to investigate whether a microfluidics assay can detect trace amounts of residual leukemia and predict relapse in acute myeloid leukemia (AML) patients in remission who have undergone…
- Trial name
- NCT03488862
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Anesthesia, Surgery
Effects of Recruitment Maneuver on Functional Residual Capacity
Recruitment maneuver is frequently used in daily anaesthesia routine to prevent athelectasia and ventilation perfusion mismatch.
- Conditions
- Anesthesia, Surgery, Atelectasis
- Trial name
- NCT04208737
- Testing
- recruitment maneuver
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul University
Epithelial Ovarian Cancer
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.
- Trial name
- NCT05212779
- Testing
- Signatera testing, Altera Testing
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
CRC (Colorectal Cancer)
A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy
The purpose of this study is to evaluate INCA33890 in the treatment of circulating tumor DNA-positive stage II/III microsatellite stable colorectal cancer after curative resection and chemotherapy.
- Trial name
- NEXERA-204 (NCT07823322)
- Testing
- INCA33890
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Pancreatic Cancer, Locally Advanced
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in borderline resectable or locally advanced pancreatic cancer.
- Trial name
- MAP-03 (NCT05802394)
- Testing
- Later-line therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Ovarian Cancer, Primary Peritoneal Cancer
Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer
The OvIP1 study is designed to examine how drug dose and perfusion temperature affect the pharmacokinetics and pharmacodynamics of cisplatin used as (hyperthermic) intraperitoneal chemoperfusion, as an adjunct to surgery, in…
- Trial name
- OvIP1 (NCT02567253)
- Testing
- Cytoreductive surgery, IPEC with Cisplatin (75mg/m²), IPEC with Cisplatin (100mg/m²)
- Where
- Belgium
- Volunteers
- 56 people
- Sponsor
- University Hospital, Ghent
Gastrointestinal Stromal Tumor
Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
RATIONALE: Surgery may remove residual disease in patients with gastrointestinal stromal tumor that is responding to imatinib mesylate.
- Trial name
- NCT00956072
- Testing
- imatinib mesylate, therapeutic conventional surgery
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.